December, 2023 - twenty30 health

GLP-1 Drugs take 2023 by Storm; Exploitative Companies and Responsible Practices in Obesity Care; Are We Poised to Eradicate Obesity?

December 31, 2023 No Comments

AT A GLANCE Science Magazine ‘…has named GLP-1 drugs the Breakthrough of the Year.’ Lars Fruergaard Jorgensen, CEO at Novo Nordisk, was anointed the Financial Times 2023 Person of the Year. Michael Albert, physician and co-founder at Accomplish Health, makes a call for responsible practices in obesity medicine. Elaine Chen and colleagues at STAT round off a terrific year of reporting on obesity care, with the quest to eradicate

GLP-1 drugs forever; Ozempic holiday; Pairing meds with bariatric surgery; new data on oral GLP-1 medication; $20M funding for weight-inclusive primary care.

December 24, 2023 No Comments

AT A GLANCE Are GLP-1 drugs a forever commitment? is the topic de jour from Shelby Livingston at Business Insider. Tina Reid at AXIOS notes a pairing of GLP-1 drugs with bariatric surgery; as opposed to an either or approach. Structure Therapeutics, released data from oral GLP-1 study drug GSBR-1290, in 94 patients with weight loss of just 3.5%, over 12-weeks. knownwell, an in-person and virtual, weight-inclusive primary care and

WeightWatchers goes all-in on GLP-1 Meds; the Year of Ozempic; Poison Control Centers increase in Calls related to Semaglutide; 63% of Older Adults want to take Meds for Obesity.

December 17, 2023 No Comments

AT A GLANCE WeightWatchers CEO Sima Sistani says we ‘…got it wrong…’ and ‘…The science has changed…’ such that WeightWatchers announced the launch of a ‘…GLP-1 Program to provide tailored behavioral support for individuals.’ ‘…Poison control centers across the US say they are seeing a steep increase in calls related to semaglutide…’ in reporting at CNN. Twin Health, a Silicon Valley startup with an AI-based dynamic model of each individual’s

Roche acquires GLP-1 Company; New York’s Bellevue Hospital in the Limelight; Just 40% still on Ozempic after One Year; 50% Lower Risk of Colon Cancer for those on GLP-1 Meds!

December 10, 2023 No Comments

AT A GLANCE Roche is ‘…acquiring Carmot Therapeutics and the company’s line of weight loss drug candidates for $2.7 billion upfront…’ in a news story from STAT. ‘Zepbound is now available at pharmacies across the U.S.…’ with a ‘…commercial savings card program…’ as per CNBC. Fast Company relays large employers have focused upon halting coverage for their employees to access GLP-1 medications; which is ‘…where eight-year-old healthcare technology company

NIH reviews Obesity in Kids; Altimmune and Pfizer report on new Obesity Drug Trials; Novo CEO wants Shared Risk Pricing for Wegovy; Ozempic vs. Mounjaro – let the Head-to-Head games begin.

December 3, 2023 No Comments

AT A GLANCE The National Institute of Health, or the NIH, held a two-day meeting this week on pharmacotherapy for obesity in children and adolescents. Pfizer announced data for their in-house GLP-1 agonist drug danuglipron, with ‘…mean placebo-adjusted weight reductions ranging from -8% to -13% at 32 weeks…’ Altimmune announced ‘…results from its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide…’, with mean weight losses of up to 15.6%, and 30%

Month: December 2023

GLP-1 Drugs take 2023 by Storm; Exploitative Companies and Responsible Practices in Obesity Care; Are We Poised to Eradicate Obesity?

GLP-1 drugs forever; Ozempic holiday; Pairing meds with bariatric surgery; new data on oral GLP-1 medication; $20M funding for weight-inclusive primary care.

WeightWatchers goes all-in on GLP-1 Meds; the Year of Ozempic; Poison Control Centers increase in Calls related to Semaglutide; 63% of Older Adults want to take Meds for Obesity.

Roche acquires GLP-1 Company; New York’s Bellevue Hospital in the Limelight; Just 40% still on Ozempic after One Year; 50% Lower Risk of Colon Cancer for those on GLP-1 Meds!

NIH reviews Obesity in Kids; Altimmune and Pfizer report on new Obesity Drug Trials; Novo CEO wants Shared Risk Pricing for Wegovy; Ozempic vs. Mounjaro – let the Head-to-Head games begin.

Categories

Archives